Fourier Intelligence

Fourier Intelligence, trading as 傅利叶智能 (Fuliye Zhineng), is a Chinese robotics company headquartered in Shanghai, founded in 2015 by Alex Gu (顾捷, Gu Jie), a mechanical engineer with previous experience at the Shanghai-based industrial-robotics company STEP. Fourier originated as a medical-and-rehabilitation-robotics company building exoskeletons and upper-limb rehabilitation devices, and pivoted to humanoid robotics in 2023 with the GR-1 platform. The company has an unusual capital-and-strategic profile for a Chinese humanoid-robotics company in that the Saudi Public Investment Fund (PIF) and Saudi NEOM are among its named strategic partners and investors.

At a glance

• Founded: 2015 in Shanghai by Alex Gu.
• Status: Private. Funding rounds itemised in industry coverage place cumulative disclosed funding in the hundreds of millions of dollars range.
• Funding: Multiple private rounds from Saudi Public Investment Fund, IDG Capital, Cybernaut Investment Group, Saudi NEOM, and additional Chinese venture firms.
• CEO: Alex Gu (Gu Jie), founder.
• Open weights: None publicly released for the humanoid platform AI stack. The hardware platforms have published technical specifications but the foundation-model and control-stack software remain proprietary.
• Flagship products: GR-1 (July 2023, the company's first humanoid robot); GR-2 (2024, second-generation humanoid); X1, X2, M2 exoskeleton and upper-limb rehabilitation platforms (the company's pre-humanoid product line, still in active development and shipping).

Origins

Alex Gu founded Fourier Intelligence in 2015 with an initial focus on rehabilitation and medical robotics, specifically lower-limb exoskeletons for stroke and spinal-cord-injury rehabilitation and upper-limb robotic-arm platforms for the same patient populations. The company's pre-humanoid product line included the X1 and X2 lower-limb exoskeletons, the M2 upper-limb rehabilitation device, and the ArmMotus M2 desktop arm-rehabilitation platform. These platforms were sold through medical-device distribution channels into rehabilitation hospitals in China, Australia, and parts of Europe.

The decision to enter the humanoid market in 2023 was framed publicly by Gu as a natural extension of the company's actuator-and-control-systems engineering capability. The GR-1 was unveiled in July 2023 at the World AI Conference in Shanghai, with the platform positioned as a research-and-development tier humanoid rather than a mass-production consumer or industrial product. The development timeline from market-entry-decision to public unveiling was roughly 18 months, drawing extensively on the actuator-and-control-system expertise the company had built for the medical-and-rehabilitation product line.

The GR-1 specifications at unveiling: 1.65 metres tall, approximately 55 kilograms in weight, with 40 degrees of freedom across the body and arms. The platform was positioned for research, education, and demonstration use cases initially, with industrial-application development planned for subsequent generations. The GR-2 in 2024 followed with mechanical-design improvements and improved control-stack integration.

The Saudi relationship was a notably unusual element of the company's 2023 and 2024 strategic narrative. The Saudi Public Investment Fund participated in the company's funding rounds, and Fourier announced strategic partnerships with the Saudi NEOM Special Zone for deployment-and-demonstration projects in Saudi Arabia. The relationship reflected both the Saudi sovereign wealth fund's broader interest in robotics and AI capability building, and Fourier's positioning as a Chinese humanoid-robotics company willing to engage with non-Chinese sovereign capital at a scale not typical for the cluster.

Mission and strategy

Fourier Intelligence's strategic positioning sits between two product lines: the established medical-and-rehabilitation robotics business that has been the company's revenue base since founding, and the newer humanoid-robotics business that started with GR-1 in 2023. The two product lines share underlying engineering capability (actuators, control systems, mechanical design) but face entirely different go-to-market channels, customer types, and competitive landscapes.

In the humanoid market, Fourier's positioning has been on research-and-development sales rather than on cost-and-volume (where Unitree leads) or enterprise-customer pipelines (where UBTECH leads). The GR-1 and GR-2 platforms have been sold primarily into academic research labs, robotics-education programs, and demonstration applications, with limited movement into mass-production industrial customer pipelines. The pricing has been higher than Unitree's G1 but lower than Western competitors, positioning Fourier as a mid-tier price point in the global research-humanoid market.

The Saudi relationship is the most-distinctive element of the company's strategy among the Chinese humanoid cluster. No other Chinese humanoid company has the same level of named-strategic-partner relationship with a Middle Eastern sovereign wealth fund. The relationship gives Fourier potential market access to Saudi NEOM, to the broader Gulf Cooperation Council region, and to Saudi-led robotics-and-AI capability-building programs that could be a meaningful customer pipeline for the GR series and for related platforms.

Models and products

• GR-1 (July 2023). First-generation humanoid platform. 1.65 metres tall, ~55 kg, 40 degrees of freedom. Targeted at research, education, and demonstration applications.
• GR-2 (2024). Second-generation humanoid platform. Improved mechanical design, improved actuator integration, larger control-stack capabilities. Continues the research-and-development positioning.
• X1 lower-limb exoskeleton (pre-2023). Rehabilitation device for stroke and spinal-cord-injury patients. Distributed through medical-device channels.
• X2 lower-limb exoskeleton (pre-2023). Improved successor to X1.
• M2 upper-limb rehabilitation device (pre-2023). Stationary upper-limb rehabilitation platform.
• ArmMotus M2 (pre-2023). Desktop arm-rehabilitation device.

Benchmarks and standing

The humanoid-robotics category lacks the standardised benchmarks of the language-model field. Standing in Fourier's case is measured through (1) the deployment breadth of the GR series in research-and-education labs globally, (2) the company's combined revenue base across the medical-rehabilitation and humanoid product lines, and (3) the strategic significance of the Saudi relationship.

On research-humanoid deployments, the GR series has been visible in multiple academic robotics labs in Europe, Asia, and North America. The unit shipment volume has not been officially itemised. On combined revenue base, the medical-rehabilitation product line has been the company's primary revenue source since founding, with the humanoid line still in the demonstration-and-development phase relative to a mature production volume. On the Saudi relationship, the named-investor status of the Saudi Public Investment Fund and the announced NEOM partnership provide a level of sovereign-capital strategic anchoring that is distinctive in the Chinese humanoid cluster.

The company's competitive positioning relative to the Chinese cluster leaders is unambiguous: Unitree is ahead on humanoid production volume and cost positioning; UBTECH is ahead on enterprise-customer pipeline and public-listing status; Agibot is ahead on robotics-foundation-model and data-infrastructure positioning. Fourier's distinctive position is the combination of the medical-rehabilitation revenue base, the academic-research humanoid market, and the Saudi strategic relationship.

Leadership

• Alex Gu (Gu Jie, Founder, Chief Executive Officer). Mechanical-engineering background. Previous engineering tenure at STEP, a Shanghai-based industrial-automation company. Founded Fourier in 2015 with initial focus on rehabilitation robotics. Continues to lead the company through the humanoid-pivot phase.
• Senior team. Approximately 400 to 600 employees as of late 2025 across the medical-rehabilitation and humanoid product lines. The senior-leadership organisation has been less publicly profiled than at competitor companies.

Funding and backers

Fourier has raised multiple private rounds since founding. Named investors include:

• Saudi Public Investment Fund (PIF). Strategic investor. The Fourier relationship is among the more substantial robotics-sector investments in PIF's broader robotics-and-AI portfolio, which also includes interests in Humain and other Middle Eastern AI infrastructure initiatives.
• IDG Capital. Multi-round participant from the company's earlier funding history.
• Cybernaut Investment Group. Multi-round participant.
• Saudi NEOM. Strategic partner with associated capital commitment.
• Additional unspecified Chinese venture firms participated in subsequent rounds.

Round sizes and post-money valuations have not been publicly itemised in detail. Industry coverage in late 2025 placed cumulative disclosed funding in the hundreds-of-millions-of-dollars range, with the most-recent named rounds in 2024 and 2025 supporting the humanoid product-line expansion and Saudi-partnership-related capability deployment.

Industry position

Fourier Intelligence is a tier-two competitor in the Chinese humanoid cluster, positioned in the academic-research-and-education humanoid segment with the distinguishing strategic asset of the Saudi sovereign-capital relationship. The competitive position behind the three primary Chinese cluster leaders (Unitree, UBTECH, Agibot) is consistent across most industry framings. The opportunity for upward repositioning depends primarily on (1) whether the humanoid product line scales into meaningful production volumes, (2) whether the Saudi strategic relationship produces meaningful deployment-and-revenue volume in the Gulf region, and (3) whether the medical-rehabilitation revenue base continues to support the company's R&D investment in the more-capital-intensive humanoid line.

The competitive question against Unitree is around cost positioning, where Fourier is at a structural disadvantage relative to Unitree's volume-and-pricing position. The competitive question against UBTECH is around enterprise-customer pipeline, where Fourier has been less visible. The competitive question against Agibot is around AI-foundation-model integration, where Fourier has emphasised hardware-and-mechanical engineering more than AI software.

Internationally Fourier competes in the academic-research humanoid market against the lower-cost SKUs of the US cohort (Apptronik, Agility Robotics, 1X) and the European competitors (Neura Robotics, Engineered Arts). The Saudi relationship gives Fourier a regional opening in the Gulf that no Chinese competitor has matched and only Humain (as the Saudi sovereign humanoid program directly) is positioned to capture.

Competitive landscape

• Chinese cluster: Unitree, UBTECH, Agibot, EngineAI, XPeng Robotics, Xiaomi Robotics. Direct domestic competitors with different vertical positionings.
• Saudi-and-Gulf cohort: Humain as the Saudi sovereign-AI program with associated humanoid capability investment. Strategic and customer relationship rather than direct competitor.
• US cohort: Figure AI, Tesla AI, Apptronik, Agility Robotics, Boston Dynamics, 1X. International competitors at higher price points.
• Other geographies: Sanctuary AI (Canada), Neura Robotics (Germany), Rainbow Robotics (South Korea), Kawada Robotics (Japan), Engineered Arts (UK).

Outlook

Open questions and watchable signals over the next 6 to 18 months:

• GR-3 generation and humanoid production volume. GR-1 in 2023 and GR-2 in 2024 established the product-line cadence. A GR-3 generation in 2026 would be a watchable signal of continued investment in the humanoid line. Production-volume disclosures (currently absent) would be informative.
• Saudi NEOM deployment progress. The strategic partnership with NEOM announced in 2024 has not produced public deployment-volume or revenue disclosures. Visible deployment in Gulf-region projects would meaningfully validate the strategic positioning.
• Medical-rehabilitation product-line trajectory. The pre-2023 medical-rehabilitation business has been the company's revenue base. Whether this revenue base continues to grow at scale, whether it remains flat, or whether the humanoid pivot diverts engineering-and-management capacity in ways that hurt the medical line will be informative.
• AI-stack partnerships. Fourier has emphasised mechanical-and-actuator engineering more than AI-foundation-model integration. Announced partnerships with Chinese frontier-model labs or with the robotics-foundation-model providers would be informative for the competitive position against Agibot.
• Funding round timing and venue. Any new named round in 2026 will produce informative valuation data. Whether the next round comes from Chinese venture firms, from Saudi sovereign capital, or from a combination will indicate the strategic centre of gravity of the company.

Sources

• Fourier Intelligence official website.
• Coverage of the GR-1 humanoid unveiling at the 2023 World AI Conference in Shanghai.
• Coverage of the Saudi Public Investment Fund's robotics-and-AI portfolio.
• Companion profiles: Unitree Robotics, UBTECH, Agibot, XPeng Robotics, Xiaomi Robotics, EngineAI for the broader Chinese humanoid cluster context, and Humain for the Saudi sovereign-AI strategic partner context.